Arcutis Biotherapeutics, Inc. (ARQT) stock
ARQTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/30403% above fair value
$27.33+0.18 (+0.66%)
Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –
Arcutis Biotherapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Arcutis Biotherapeutics's price to sales ratio was 7.7× on Nov 11, 2026, against 11.6× a year earlier. Over the last 4 years it ranged from 2.3× to 267.9×, with a median of 9.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.7× | −3.3 |
| 2025 | Dec 31, 2025 | 11.0× | −0.8 |
| 2024 | Dec 31, 2024 | 11.8× | +7.7 |
| 2023 | Dec 29, 2023 | 4.1× | – |
See a number that looks wrong?